Rybelsus from Novo Nordisk is officially the first oral GLP-1 drug approved for this indication. The FDA's decision was based on the SOUL trial, which included data from more than 9,000 patients with type 2 diabetes. Rybelsus from Novo Nordisk is officially the first oral GLP-1 drug approved for this indication. The FDA's decision was based on the SOUL trial, which included data from more than 9,000 patients with type 2 diabetes. | | |
|
PET has already gained significant momentum in recent years. Now, researchers are pointing to another possible use for the popular imaging modality: assessing carotid artery atherosclerosis. PET has already gained significant momentum in recent years. Now, researchers are pointing to another possible use for the popular imaging modality: assessing carotid artery atherosclerosis. | | |
|
The study's authors questioned if these patients should even be given oral anticoagulation as currently recommended. The study's authors questioned if these patients should even be given oral anticoagulation as currently recommended. | | |
|
No medications are currently approved for the treatment of nonobstructive hypertrophic cardiomyopathy. Could a new drug from Imbria Pharmaceuticals be the first? No medications are currently approved for the treatment of nonobstructive hypertrophic cardiomyopathy. Could a new drug from Imbria Pharmaceuticals be the first? | | |
|
A facility outside the United States has received the American Heart Association's Comprehensive Heart Failure Center Certification for the first time. A facility outside the United States has received the American Heart Association's Comprehensive Heart Failure Center Certification for the first time. | | |
|
|
Imagers can now identify vulnerable plaques that were once very challenging to find. The next steps include improving the screening process and determining which lesions need to be treated right away. Imagers can now identify vulnerable plaques that were once very challenging to find. The next steps include improving the screening process and determining which lesions need to be treated right away. | | |
|
Prescribing these drugs to TAVR patients could improve certain clinical outcomes, according to a new study of nearly 27,000 adults. Prescribing these drugs to TAVR patients could improve certain clinical outcomes, according to a new study of nearly 27,000 adults. | | |
|
More research is still required, but Field Medical's FieldForce Ablation System may represent a significant step forward in the treatment of scar-related ventricular tachycardia. More research is still required, but Field Medical's FieldForce Ablation System may represent a significant step forward in the treatment of scar-related ventricular tachycardia. | | |
|
The new software provides automated measurements that save time and improve the care of aortic aneurysm patients. The new software provides automated measurements that save time and improve the care of aortic aneurysm patients. | | |
|
|
The popularity of various obesity management medications has increased significantly in recent years. According to a new analysis of more than 60,000 patients, some of these drugs are associated with more cardiovascular benefits than others. The popularity of various obesity management medications has increased significantly in recent years. According to a new analysis of more than 60,000 patients, some of these drugs are associated with more cardiovascular benefits than others. | | |
|
ICE is gaining momentum as a helpful imaging option during structural heart interventions, according to a new SCAI position statement. TEE and TTE remain incredibly important, but there are times when ICE can provide the guidance necessary. ICE is gaining momentum as a helpful imaging option during structural heart interventions, according to a new SCAI position statement. TEE and TTE remain incredibly important, but there are times when ICE can provide the guidance necessary. | | |
|
The vMap System from San Diego-based Vektor Medical turns 12-lead ECGs into 3D maps of the heart. It has already been cleared by the FDA. The vMap System from San Diego-based Vektor Medical turns 12-lead ECGs into 3D maps of the heart. It has already been cleared by the FDA. | | |
|
|
It is estimated that less than 20% of eligible patients in the U.S. adhere to LCS recommendations, despite numerous studies highlighting the exam’s effectiveness. It is estimated that less than 20% of eligible patients in the U.S. adhere to LCS recommendations, despite numerous studies highlighting the exam’s effectiveness. | | |
|
Experts are working to develop agents they say can enhance imaging studies without the risks associated with traditional contrast media. Experts are working to develop agents they say can enhance imaging studies without the risks associated with traditional contrast media. | | |
|
